5AM Venture Management portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
5AM Venture Management reported a $288M portfolio of 16 positions to the SEC as of the end of Q2 2026. Its largest positions are MPLT, TYRA, TRDA. During the quarter it exited Erasca and GH Research.
Sections with a free account
What changed this quarter
4 positions with a change (1 trimmed, 3 sold); also, 1 exited through an acquisition or merger. 4 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Erasca−15.7 ppof portfolioSold out15.7% → —
- GH Research−2.2 ppof portfolioSold out2.2% → —
- Surrozen−30%fewer sharesReduced3.1% → 2.4%
- Rallybio−0.7 ppof portfolioSold out0.7% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- MapLight TherapeuticsMPLT11.8%
- Tyra BiosciencesTYRA11.4%
- Entrada TherapeuticsTRDA10.4%
- PharvarisPHVS9.6%
- CAMP4 TherapeuticsCAMP8.9%
- Artiva BiotherapeuticsARTV7.9%
- Tectonic TherapeuticTECX7.2%
- Zentalis PharmaceuticalsZNTL6.7%
- Celldex TherapeuticsCLDX6.4%
- EyePointEYPT5.2%
- BiohavenBHVN3.8%
- SurrozenSRZN2.4%
- Skye Bioscience2.3%
- ALX Oncology HoldingsALXO2.2%
- Protara TherapeuticsTARA1.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 16
Q2 2026: 86%
Q2 2026: 9.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Not counted as a concentrated manager: it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Dalal StreetInvestment firm · $327M
- MuhlenkampInvestment firm · $345M
- Matthew 25 ManagementInvestment firm · $345M
- RR Advisors$346M
- Weybosset Research & Management$347M
- Stonehill Capital ManagementInvestment firm · $350M